Information Provided By: 
Fly News Breaks for October 11, 2018
NITE
Oct 11, 2018 | 07:15 EDT
Cantor Fitzgerald analyst Elemer Piros started Nightstar Therapeutics with an Overweight rating and $36 price target. Nightstar is developing AAV-vector-based gene therapies for ophthalmological indications, Piros tells investors in a research note. The analyst has a positive outlook for Nightstar based on positive data shown in multiple Phase 2 investigator sponsor led trials, a potential first mover advantage, and proof of concept in multiple ocular gene therapy trials.
News For NITE From the Last 2 Days
There are no results for your query NITE
